読み込み中
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.
前日終値
$1.10
−$0.025 · -2.22%
日中の時刻はETです。市場データは遅延する場合があります。
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.
日中レンジ
現在 $1.10
52週レンジ
現在 $1.10
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
46
適正価値
センチメント
56
まちまち
リスク
86
極めて高いリスク
モメンタム
25
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.
日中レンジ
現在 $1.10
52週レンジ
現在 $1.10
営業利益
純利益
| 指標（GBP） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 研究開発 | 1273.7万 GBP | 1801.7万 GBP | 2506.2万 GBP | 3642.6万 GBP | 3683.4万 GBP |
| 販売・一般管理 | 809.6万 GBP | 498.8万 GBP | 606.3万 GBP | 729.1万 GBP | 852.9万 GBP |
| 営業費用 | 2011万 GBP | 2280.9万 GBP | 3278.4万 GBP | 3912.2万 GBP | 4790.5万 GBP |
| 受取利息 | 38.6万 GBP | 35.8万 GBP | 75.4万 GBP | 66.9万 GBP | 10.3万 GBP |
| 減価償却費と償却費 | 27.4万 GBP | 52.2万 GBP | 57.5万 GBP | 73.2万 GBP | 94.2万 GBP |
| 営業利益 | −2011万 GBP | −2280.9万 GBP | −3278.4万 GBP | −3912.2万 GBP | −4790.5万 GBP |
| 純利益 | −2935.3万 GBP | −1899.7万 GBP | −2763.2万 GBP | −3202.1万 GBP | −4053.3万 GBP |
会社概要が更新されました 2026年10月10日.
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
